<SEC-DOCUMENT>0001628280-23-013356.txt : 20230427
<SEC-HEADER>0001628280-23-013356.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427071856
ACCESSION NUMBER:		0001628280-23-013356
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230427
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BAXTER INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000010456
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				360781620
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-04448
		FILM NUMBER:		23851856

	BUSINESS ADDRESS:	
		STREET 1:		ONE BAXTER PKWY
		STREET 2:		DF2-1W
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015
		BUSINESS PHONE:		8479482000

	MAIL ADDRESS:	
		STREET 1:		ONE BAXTER PARKWAY
		STREET 2:		DF2-1W
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BAXTER TRAVENOL LABORATORIES INC
		DATE OF NAME CHANGE:	19880522

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BAXTER LABORATORIES INC
		DATE OF NAME CHANGE:	19760608
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bax-20230427.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:6253cd8d-ebc9-425e-9b92-f4fbc7470365,g:d94e7b98-a6da-4eb0-ae1e-1ab735b5265d,d:9e45022694ba44c8a6d57923ba0af02b--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:bax="http://www.baxter.com/20230427" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bax-20230427</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl80L2ZyYWc6ZTBhZWNkMWM2ZGZhNGUxMGE1NTc0MjBjYTdlNzg4YjYvdGFibGU6NzZjOGMzNTA5NGVhNGQyZGFmNDZmM2NmNWFmMTZjOTAvdGFibGVyYW5nZTo3NmM4YzM1MDk0ZWE0ZDJkYWY0NmYzY2Y1YWYxNmM5MF8yLTEtMS0xLTE0MjYyMg_21ad4116-4b4f-42e8-88e2-8415609889c5">0000010456</ix:nonNumeric><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl80L2ZyYWc6ZTBhZWNkMWM2ZGZhNGUxMGE1NTc0MjBjYTdlNzg4YjYvdGFibGU6NzZjOGMzNTA5NGVhNGQyZGFmNDZmM2NmNWFmMTZjOTAvdGFibGVyYW5nZTo3NmM4YzM1MDk0ZWE0ZDJkYWY0NmYzY2Y1YWYxNmM5MF8zLTEtMS0xLTE0MjYyMg_6cf0552a-e447-469e-9268-c34348567890">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bax-20230427.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000010456</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000010456</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:CommonStock1.00PerValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000010456</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:CommonStock1.00PerValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea79023a6fe4549954e7859fe72a386_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000010456</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:GlobalNotes04Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000010456</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:GlobalNotes13Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a12f6738785458cba103994ca1398b5_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000010456</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:GlobalNotes13Due2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9e45022694ba44c8a6d57923ba0af02b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl84Mg_2633f316-2b96-49c3-bc17-8cc643124381">8-K</ix:nonNumeric> </span></div><div style="margin-top:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;13 OR 15(D) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl8yMjM_03a9874a-684c-4f2e-8095-670245a9146b">April&#160;27, 2023</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8wLTAtMS0xLTE0MjYyMg_d31d9a6e-70c0-4b65-ae17-5fcc0f56e38e">Baxter International Inc.</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8zLTAtMS0xLTE0MjYyMg_1f7762c6-67f1-4007-9c68-87293dac9949">Delaware</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV82LTAtMS0xLTE0MjYyMg_f7e2a50b-b5c1-4615-aa19-252e413341d3">1-4448</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV82LTEtMS0xLTE0MjYyMg_673fc011-38e4-453b-9e43-1304896a0b4e">36-0781620</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTAtMS0xLTE0MjYyMi90ZXh0cmVnaW9uOmIxMGExNjQ1NGYxOTRkNGFiYTBiN2JlODEwNmM5Nzk5XzQ_4fad1adf-cb94-4837-802f-71f1660b6be8">One Baxter Parkway</ix:nonNumeric>, <ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTAtMS0xLTE0MjYyMi90ZXh0cmVnaW9uOmIxMGExNjQ1NGYxOTRkNGFiYTBiN2JlODEwNmM5Nzk5Xzg_ae9c2d7a-3981-4987-9ed0-083f6c10466f">Deerfield</ix:nonNumeric>, <ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTAtMS0xLTE0MjYyMi90ZXh0cmVnaW9uOmIxMGExNjQ1NGYxOTRkNGFiYTBiN2JlODEwNmM5Nzk5XzEy_a3cc51aa-c741-407d-9dad-bcaa444f5995">Illinois</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTEtMS0xLTE0MjYyMg_25bd04c4-b7c2-4676-ba26-540de678af0a">60015</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8xMi0wLTEtMS0xNDI2MjIvdGV4dHJlZ2lvbjoyYzFlNDQ0MDk4Nzk0ZTgxYjAzYjkwNTgxYWZmNmJkNl81_d0d3399d-3c3f-4775-b98b-82a18cff76c0">224</ix:nonNumeric>)<ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8xMi0wLTEtMS0xNDI2MjIvdGV4dHJlZ2lvbjoyYzFlNDQ0MDk4Nzk0ZTgxYjAzYjkwNTgxYWZmNmJkNl84_9422a04e-1303-409c-85fa-6d485c3527e8">948-2000</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Former name or former address, if changed since last report)</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl8zOTk_cbb5f40e-71bb-4e28-8322-95f21341208c">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl80OTE_5fbf76df-fe32-4d1b-baf8-b73165128f8c">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl81ODQ_863bcac9-1334-4890-bcf7-a0b3cad6a3a6">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl82OTM_1d120f88-ebc6-4e67-ac24-c1a07a1cb7ac">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTAtMS0xLTE0MjYyMg_74de5d99-984c-4081-b331-6c670b434742"><ix:nonNumeric contextRef="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTAtMS0xLTE0MjYyMg_d5d672e7-a625-4d69-9520-a7b29872f601">Common Stock, $1.00 par value</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTItMS0xLTE0MjYyMg_0ed05bdf-d5b6-4bb1-a2de-17e52d3ab8bb"><ix:nonNumeric contextRef="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTItMS0xLTE0MjYyMg_29d1994e-faa1-45ed-bb00-b785c58442bf">BAX (NYSE)</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTQtMS0xLTE0MjYyMg_5bc9343f-c65b-40b6-95cf-1a4cf0bd8947">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8yLTQtMS0xLTE0MjYyMg_d808e90d-e9fb-46c4-ab23-1728e11ba517">Chicago Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icea79023a6fe4549954e7859fe72a386_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTAtMS0xLTE2MTE2MQ_ffe09d41-47dd-4edb-8897-6d5781564f56">0.4% Global Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icea79023a6fe4549954e7859fe72a386_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTItMS0xLTE2MTE2MQ_a025aa46-b4ad-4070-9207-0bc7a962f586">BAX 24</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icea79023a6fe4549954e7859fe72a386_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTQtMS0xLTE2MTE2MQ_59b966bf-8fb4-4588-92ee-2a01f59349f4">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTAtMS0xLTE0MjYyMg_1895d223-d635-4795-9117-4f6402312acb">1.3% Global Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTItMS0xLTE0MjYyMg_fe0bef07-9d94-499f-bdfe-a0abd135d04d">BAX 25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTQtMS0xLTE0MjYyMg_98e67e43-bf45-444f-91eb-4cdd50cf1314">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a12f6738785458cba103994ca1398b5_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl80LTAtMS0xLTE0MjYyMg_4cc76c65-4fde-43d8-9aea-bb38aae8cd63">1.3% Global Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a12f6738785458cba103994ca1398b5_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl80LTItMS0xLTE0MjYyMg_258a40dd-f1f1-4d21-8e8f-0b325df0d0cc">BAX 29</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a12f6738785458cba103994ca1398b5_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl80LTQtMS0xLTE0MjYyMg_564886d4-030f-417a-8660-056821460620">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter):</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl8xMTAy_0641c141-89aa-4b13-b24f-a26e5fb98c29">&#9744;</ix:nonNumeric> Emerging growth company</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act: &#160;&#160;&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9e45022694ba44c8a6d57923ba0af02b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl83L2ZyYWc6Njk0MWY5NmFhYTIxNDgwMTgwYjUxMjVjOTE5NjliZjQvdGV4dHJlZ2lvbjo2OTQxZjk2YWFhMjE0ODAxODBiNTEyNWM5MTk2OWJmNF81NDk3NTU4MTQxNDM_03a9874a-684c-4f2e-8095-670245a9146b">April&#160;27, 2023</ix:nonNumeric>, Baxter International Inc. (the Company) issued an earnings press release for the period ended March&#160;31, 2023. The press release, including attachments, is furnished as Exhibit 99.1 to this report.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i9e45022694ba44c8a6d57923ba0af02b_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Exhibits.</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit&#160;Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="bax-20230331xex991.htm">Press Release Dated April 27, 2023</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9e45022694ba44c8a6d57923ba0af02b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date: April&#160;27, 2023</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BAXTER INTERNATIONAL INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">/s/ James K. Saccaro</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James K. Saccaro</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bax-20230331xex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7352449d055545349209a41fc56acfe2_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="margin-top:10pt;text-align:right"><font><br></font></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt;text-align:right"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">FOR IMMEDIATE RELEASE</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BAXTER REPORTS FIRST-QUARTER 2023 RESULTS</font></div><div style="margin-top:10pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">First-quarter revenue of $3.65 billion decreased 2% on a reported basis and increased 2% on a constant currency basis</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">First-quarter U.S. GAAP earnings per share (EPS) totaled $0.09&#59; Adjusted EPS totaled $0.59 </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Baxter expects full-year 2023 sales growth of 1% to 2% on a reported basis and &#126;1% on a constant currency basis</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Baxter expects full-year U.S. GAAP EPS of $1.16 to $1.31 and adjusted EPS of $2.85 to $3.00</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">DEERFIELD, Ill., APRIL 27, 2023 &#8211;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Baxter International Inc. (NYSE&#58;BAX), a global medtech leader, today reported results for the first quarter of 2023.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8220;Baxter&#8217;s performance in the first quarter reflects sustained demand for our medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace,&#8221; said Jos&#233; (Joe) E. Almeida, chairman, president and chief executive officer. &#8220;I am confident that the transformational actions announced earlier this year, and currently underway, will help us advance our performance, fueling enhanced agility, efficiency, and resilience as we navigate an evolving landscape. Our goal, as always, is to drive increasing impact and value for the patients, clinicians, investors and numerous other stakeholder communities that depend on us.&#8221; </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-Quarter Financial Results</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Worldwide sales in the first quarter totaled approximately $3.65 billion, a decrease of 2% on a reported basis and an increase of 2% on a constant currency basis, exceeding the company&#8217;s previously issued guidance.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">______________________</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See tables to the press release for reconciliations of non-GAAP measures used in this press release to the corresponding U.S. GAAP measures.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Sales in the U.S. totaled $1.73 billion, decreasing 1% on a reported basis. International sales of $1.92 billion decreased 2% on a reported basis and increased 4% at constant currency rates.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Sales performance at constant currency rates reflects overall positive demand across the portfolio, supported by a continued recovery in patient and procedure volumes following the height of the COVID-19 pandemic, in combination with generally stabilizing macroeconomic conditions and an improvement in recent supply chain challenges. Sales growth in the quarter was primarily driven by strength in Advanced Surgery, Front Line Care, Pharmaceuticals and Renal Care. First-quarter performance was partially offset by expected declines in Acute Therapies and BioPharma Solutions as well as in Patient Support Systems, which reflected a slowdown in capital spending for certain healthcare products.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Please see the attached schedules accompanying this press release for additional details on sales performance in the quarter, including breakouts by Baxter&#8217;s product categories and segments.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">For the first quarter, net income attributable to Baxter was $44 million, or $0.09 per diluted share, a decline of 36% on a U.S. GAAP (Generally Accepted Accounting Principles) basis. These results include special items totaling $253 million after tax, which were primarily related to intangible asset amortization, business optimization and separation costs. On an adjusted basis, net income attributable to Baxter totaled $297 million, or $0.59 per diluted share, a 37% decrease. Results in the quarter exceeded the company&#8217;s previously issued guidance, driven primarily by better-than-expected sales performance.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Advancing Strategic Transformation Initiatives</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Baxter continues to execute against a range of strategic objectives announced in early 2023, focused on enhancing patient outcomes, innovation, efficiency and long-term shareholder value&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">The company is implementing a new operating model to realign its 10 businesses, region-based commercial geographies, and centralized manufacturing and supply chain operations into four vertically integrated global business segments&#58; Medical Products and Therapies&#59; Healthcare Systems and Technologies&#59; Pharmaceuticals and BioPharma Solutions&#59; and Kidney Care (through completion of the proposed spinoff). The company believes this new model will help fuel greater performance through enhanced strategic clarity, accountability, speed and innovation across the new segments. Baxter expects to report quarterly performance in line with the new operating model beginning in the second half of 2023.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.8pt">Progress is advancing on the proposed spinoff of Baxter&#8217;s Kidney Care segment (comprised of the company&#8217;s Renal Care and Acute Therapies product categories) into an independent, publicly traded company, with a preliminary operating model and organizational design now identified. The spinoff is currently expected to occur by July 2024 or earlier, subject to customary conditions.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Business Highlights</font></div><div style="margin-bottom:6pt;text-indent:40.5pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Baxter continues to advance its strategic priorities in pursuit of its Mission to Save and Sustain Lives. Among recent highlights, the company&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.8pt">Resubmitted the </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Novum IQ</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> large volume pump (LVP) for U.S. FDA 510(k) clearance. The pump is part of Baxter&#8217;s leading edge </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Novum IQ</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> infusion platform, which includes both large volume and syringe (SYR) infusion pumps. The platform features Baxter&#8217;s </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Dose IQ</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Safety Software and </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">IQ Enterprise</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Connectivity Suite, intuitive digital health technologies developed to protect patients, manage devices, and provide advanced insights. The </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Novum IQ </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">SYR is now in use in the U.S. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Launched </font><font style="color:#0000ff;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">ZOSYN</font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline"> (piperacillin and tazobactam) Injection premix</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> in the U.S. </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Zosyn</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter&#8217;s proprietary single-dose </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Galax</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">y containers, which enable premixed medications to have a longer shelf life. Its frozen premix formulation helps support patient safety, simplify medication preparation and improve operational efficiencies.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Commercially launched the new </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">Baxter Patient Warming system</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, which minimizes risks associated with forced air warming, reduces noise and waste in the operating room, and lessens the burden on clinician workflows. The updated system eliminates the need for disposables, as the warming technology is built into the table pad and employs reusable conductive warming blankets that can reach temperatures of 43 degrees Celsius.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.8pt">Launched </font><font style="color:#0000ff;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">Floseal + Recothrom</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, the first and only active flowable hemostat with a recombinant thrombin, resulting in 1.5 times faster preparation. </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Floseal + Recothrom</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> has </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:31.5pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:31.5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="margin-bottom:6pt;padding-left:31.5pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:31.5pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:31.5pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">a thrombin component manufactured using recombinant DNA technology, and therefore contains no human blood components and eliminates reliance on human blood donations. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.8pt">Introduced the </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">ReadyConnect System</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">for Baxter&#8217;s</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:174%"> </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Centrella Smart+ Bed</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">. This innovative system delivers reliable, cable-free connectivity between the hospital bed and most nurse call systems on the market, and requires no wireless network, incremental server software licenses, or other IT resources from the customer.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:10.8pt">Launched </font><font style="color:#0000ff;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">ExactaMix Pro</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, a next generation automated nutrition compounder. This new technology builds on Baxter&#8217;s original, industry leading </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">ExactaMix</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> automated nutrition compounder, which has been used in 1,000+ hospitals and compounding centers to create more than 100 million bags of medications customized to individual patients&#8217; needs. </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">ExactaMix Pro</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">offers a wide array of enhancements designed to strengthen security, improve customer experience and offer stronger data reporting capabilities. It is also the first and, to date, only automated compounder certified to the U.S. FDA-recognized UL 2900-2-1 cybersecurity standard.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:10.8pt">Announced a </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">collaborative research agreement</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> with life sciences company Miromatrix to help support additional treatment options for patients with acute liver failure (ALF). Miromatrix has developed a new therapy called </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">miroliver</font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">ELAP</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">,</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> which combines its single-use bioengineered liver with Baxter&#8217;s </font><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">PrisMax</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> system and is designed to provide external support to the patient&#8217;s native liver as a bridge to transplant or bridge to recovery. The agreement includes an intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients.</font></div><div style="margin-bottom:6pt;text-indent:40.5pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Among recent corporate responsibility highlights, Baxter and the Baxter International Foundation advanced support for disaster relief in response to February&#8217;s devastating earthquake in Turkey and Syria. Support included cash grants and product donations managed through humanitarian partners Direct Relief and Americares.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2023 Financial Outlook</font></div><div style="margin-bottom:6pt;text-indent:40.3pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">For full-year 2023&#58; Baxter now expects U.S. GAAP earnings of </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$1.16</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> to </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$1.31</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> per diluted share and adjusted earnings, before special items, of $2.85 to $3.00 per diluted share. The </font></div><div style="margin-bottom:6pt;text-indent:40.3pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="margin-bottom:6pt;text-indent:40.3pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:40.3pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">company expects sales growth of 1% to 2% on a reported basis and approximately 1% on a constant currency basis. </font></div><div style="margin-bottom:6pt;text-indent:40.5pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">For second-quarter 2023&#58; The company expects sales growth of approximately 1% to 2% on a reported basis and 2% to 3% on a constant currency basis. The company expects U.S. GAAP earnings of </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$0.18</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> to $0.20 per diluted share and adjusted earnings, before special items, of $0.59 to $0.61 per diluted share.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-Quarter 2023 Earnings Conference Call</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%">            A webcast of Baxter&#8217;s first-quarter 2023 conference call for investors can be accessed live from a link in the Investor Relations section of the company&#8217;s website at </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">www.baxter.com</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> beginning at 7&#58;30 a.m. CDT on April 27, 2023. Please see </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">www.baxter.com</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> for more information regarding this and future investor events and webcasts.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">About Baxter</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Every day, millions of patients, caregivers and healthcare providers rely on Baxter&#8217;s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we&#8217;ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter&#8217;s employees worldwide are now building upon the company&#8217;s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.baxter.com</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and follow us on </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Twitter</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LinkedIn</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Facebook</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Non-GAAP Financial Measures </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net sales growth rates are presented on a constant currency basis. These non-GAAP financial measures provide information on the percentage change in net sales growth as if foreign currency exchange rates had remained constant between the prior and current periods. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide the company&#8217;s detailed reconciliations to the corresponding U.S. GAAP financial measures) are&#58; adjusted gross margin, adjusted selling, general, and administrative expenses, adjusted research and development expenses, adjusted other operating income, net, adjusted operating income, adjusted income before income taxes, adjusted income tax expense, adjusted net income, adjusted net income attributable to Baxter stockholders and adjusted diluted earnings per share. Those non-GAAP financial measures exclude the impact of special items. For the quarters ended March 31, 2023 and 2022, special items for one or more periods included intangible asset amortization, business optimization items, acquisition and integration items, divestiture-related costs, expenses related to European medical devices regulation and product-related items. These items are excluded because they are highly variable or unusual and of a size </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that may substantially impact the company&#8217;s reported operations for a period. Additionally, intangible asset amortization is excluded as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and the company&#8217;s Board of Directors assess performance.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This release and the accompanying tables also include free cash flow, a non-GAAP financial measure that Baxter defines as operating cash flow less capital expenditures. Free cash flow is used by management and the company&#8217;s Board of Directors to evaluate the cash generated from Baxter&#8217;s operating activities each period after deducting its capital spending. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This release also includes forecasts of certain of the aforementioned non-GAAP measures on a forward-looking basis as part of the company&#8217;s financial outlook for upcoming periods.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-GAAP financial measures may enhance an understanding of the company&#8217;s operations and may facilitate an analysis of those operations, particularly in evaluating performance from one period to another. Management believes that non-GAAP financial measures, when used in conjunction with the results presented in accordance with U.S. GAAP and the company&#8217;s reconciliations to corresponding U.S. GAAP financial measures (which are included in the tables accompanying this release), may enhance an investor&#8217;s overall understanding of the company&#8217;s past financial performance and prospects for the future. Accordingly, management uses these non-GAAP measures internally in financial planning, to monitor business unit performance, and, in some cases, for purposes of determining incentive compensation. This information should be considered in addition to, and not as substitutes for, information prepared in accordance with U.S. GAAP.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Forward-Looking Statements </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:113%">This release includes forward-looking statements concerning the company&#8217;s financial results (including the outlook for second quarter and full-year 2023) and business development and regulatory activities (including anticipated cost savings). These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements&#58; the company&#8217;s ability to execute and complete strategic initiatives, asset dispositions and other transactions, including the proposed spinoff of the company&#8217;s Renal Care and Acute Therapies product categories&#59; the company&#8217;s plans to simplify the company&#8217;s operating model and manufacturing footprint and the company&#8217;s review of strategic alternatives (including a potential sale) for the company&#8217;s BioPharma Solutions product category, the timing for such transactions, the ability to satisfy any applicable conditions and the expected proceeds, consideration and benefits&#59; failure to accurately forecast or achieve the company&#8217;s short- and long-term financial improvement performance and goals (including with respect to the company&#8217;s strategic actions)&#59; the company&#8217;s ability to execute on its capital allocation plans, including the company&#8217;s debt repayment plans, the timing and amount of any dividends, share repurchases and acquisition proceeds and the capital structure of the public company that the company expects to form as a result of the proposed spinoff (and the resulting capital structure for the remaining company)&#59; the impact of global economic conditions (including, among other things, inflation levels, interest rates, financial market volatility, banking crises, the potential for a recession, the ongoing war in Ukraine, the related economic sanctions being imposed globally in response to the conflict and potential trade wars) and continuing public health crises, pandemics and epidemics, such as the ongoing COVID-19 pandemic, or the anticipation of any of the foregoing, on the company&#8217;s operations and on the company&#8217;s employees, customers and </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:113%">suppliers, including foreign governments in countries in which the company operates&#59; downgrades to the company&#8217;s credit ratings or ratings outlooks, and the related impact on the company&#8217;s funding costs and liquidity&#59; demand for and market acceptance risks for and competitive pressures related to new and existing products (including challenges with the company&#8217;s ability to accurately predict changing consumer preferences and future expenditures, which has led to and may continue to lead to increased inventory levels, and needs and advances in technology and the resulting impact on customer inventory levels and the impact of reduced hospital admission rates and elective surgery volumes), and the impact of those products on quality and patient safety concerns&#59; the continuity, availability and pricing of acceptable raw materials and component parts (and the company&#8217;s ability to pass some or all of these costs to the company&#8217;s customers through recent price increases or otherwise), and the related continuity of the company&#8217;s manufacturing and distribution and those of the company&#8217;s suppliers&#59; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization or supply difficulties (including as a result of natural disaster, public health crises and epidemics&#47;pandemics, regulatory actions or otherwise)&#59; product development risks, including satisfactory clinical performance and obtaining and maintaining required regulatory approvals (including as a result of evolving regulatory requirements), the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle&#59; the company&#8217;s ability to finance and develop new products or enhancements on commercially acceptable terms or at all&#59; loss of key employees, the occurrence of labor disruptions or the inability to identify and recruit new employees&#59; product quality or patient safety issues leading to product recalls, withdrawals, launch delays, warning letters, import bans, sanctions, seizures, litigation, or declining sales, including the focus on evaluating product portfolios for the potential presence or formation of nitrosamines&#59; breaches or failures of the company&#8217;s information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft (as a result of remote working arrangements or otherwise)&#59; future actions of (or failures to act or delays in acting by) FDA, the European Medicines Agency or any other regulatory body or government authority (including the SEC, Department of Justice, the Federal Trade Commission, Centers for Medicare &#38; Medicaid Services or the Attorney General of any State) that could delay, limit or suspend product development, manufacturing, sale or reimbursement or result in seizures, recalls, injunctions, monetary sanctions or criminal or civil liabilities, including the continued delay in lifting the warning letter at the company&#8217;s Ahmedabad facility&#59; failures with respect to the company&#8217;s quality, compliance or ethics programs&#59; future actions of third parties, including third-party payers and the company&#8217;s customers and distributors (including group purchasing organizations and integrated delivery networks), the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the United States or foreign governments&#59; the outcome of pending or future litigation, including the opioid, ethylene oxide and Linet antitrust litigation or other claims&#59; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies&#59; global regulatory, trade and tax policies (including with respect to climate change and other sustainability matters)&#59; the ability to protect or enforce the company&#8217;s owned or in-licensed patent or other proprietary rights (including trademarks, copyrights, trade secrets and know-how) or patents of third parties preventing or restricting the company&#8217;s manufacture, sale or use of affected products or technology&#59; the impact of any goodwill or other intangible asset impairments on the company&#8217;s operating results&#59; fluctuations in foreign exchange and interest rates&#59; any changes in law concerning the taxation of income (whether with respect to current or future tax reform)&#59; actions by tax </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="g782573page6aa01.jpg" src="g782573page6aa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:113%">authorities in connection with ongoing tax audits&#59; and other risks identified in Baxter&#8217;s most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter&#8217;s website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Baxter, Centrella, Dose IQ, ExactaMix, ExactaMix Pro, Floseal, Galaxy, IQ Enterprise, Novum IQ, PrisMax, ReadyConnect, Recothrom and Zosyn are registered trademarks of Baxter International Inc. or its subsidiaries. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Miroliver and miroliverELAP are registered trademarks of Miromatrix Medical, Inc.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:113%"> </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Any other trademarks or product brands appearing herein are the property of their respective owners.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Media Contact</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Steve Brett, (224) 948-5353</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">media&#64;baxter.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Investor Contact</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Clare Trachtman, (224) 948-3020</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:115%">###</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="i7352449d055545349209a41fc56acfe2_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAXTER &#8212; PAGE 9</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAXTER INTERNATIONAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share and percentage data)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended <br>March 31, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET SALES</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,649</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,707&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">COST OF SALES</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,359&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GROSS MARGIN</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,347</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,348&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">% of Net Sales</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">36.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">36.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">0.5&#160;pts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,010</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">% of Net Sales</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">27.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">28.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(0.7&#160;pts)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RESEARCH AND DEVELOPMENT EXPENSES</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">% of Net Sales</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">4.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">0.5&#160;pts</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OTHER OPERATING INCOME, NET</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OPERATING INCOME </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">186</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">% of Net Sales</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">4.4&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">0.7 pts</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INTEREST EXPENSE, NET</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OTHER INCOME, NET</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INCOME BEFORE INCOME TAXES</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INCOME TAX EXPENSE </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">% of Income Before Income Taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">35.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">22.3&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">13.4 pts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EARNINGS PER SHARE</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">505</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">507</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADJUSTED OPERATING INCOME (excluding special items)&#185;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">503</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADJUSTED INCOME BEFORE INCOME TAXES (excluding special items)&#185;</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">387</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS (excluding special items)&#185;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">297</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADJUSTED DILUTED EPS (excluding special items)&#185;</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to page 10 for a description of the adjustments and a reconciliation to U.S. GAAP measures.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7352449d055545349209a41fc56acfe2_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAXTER &#8212; PAGE 10</font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAXTER INTERNATIONAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Adjustments and Reconciliation of U.S. GAAP to&#160;Non-GAAP&#160;Measures</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in millions)</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company&#8217;s U.S. GAAP results for the three months ended March&#160;31, 2023 included special items which impacted the U.S. GAAP measures as follows&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Margin</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General and Administrative Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development Expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Operating Income, Net</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Income Taxes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax Expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income </font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Baxter Stockholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted Earnings Per Share</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,347</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,010</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported percent of net sales (or percent of income before income taxes for income tax expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business optimization items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European medical devices regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,505</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">845</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">298</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted percent of net sales (or adjusted percent of income before income taxes for income tax expense)</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company&#8217;s U.S. GAAP results for the three months ended March&#160;31, 2022 included special items which impacted the U.S. GAAP measures as follows&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.058%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Margin</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General and Administrative Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Operating Expense, Net</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Income </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Income Taxes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax Expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Baxter Stockholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted Earnings Per Share</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,348</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,052</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported percent of net sales (or percent of income before income taxes for income tax expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business optimization items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European medical devices regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product-related items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,670</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">666</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">597</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">473</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">471</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted percent of net sales (or adjusted percent of income before income taxes for income tax expense)</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The company&#8217;s results in 2023 and 2022 included intangible asset amortization expense of $162 million ($126 million, or $0.25 per diluted share, on an&#160;after-tax&#160;basis) and $217 million ($169 million, or $0.33 per diluted share, on an&#160;after-tax&#160;basis), respectively.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The company&#8217;s results in 2023 and 2022 included charges of $134 million ($107 million, or $0.21 per diluted share, on an&#160;after-tax&#160;basis) and $81 million ($61 million, or $0.12 per diluted share, on an&#160;after-tax&#160;basis), respectively, associated with its execution of programs to optimize its organization and cost structure. These restructuring and other business optimization costs included actions related to its current implementation of a new operating model intended to simplify and streamline its operations, its integration of Hillrom, rationalization of certain manufacturing and distribution facilities and transformation of certain general and administrative functions.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The company&#8217;s results in 2023 included $7 million ($5 million, or $0.01 per diluted share, on an&#160;after-tax&#160;basis) of net benefits from acquisition and integration-related items. That amount includes $13 million of net gains from changes in the estimated fair values of contingent consideration liabilities, partially offset by $6 million of integration costs, which primarily included third party consulting costs related to its integration of Hillrom. The company&#8217;s results in 2022 included $171 million ($141 million, or $0.28 per diluted share, on an after-tax basis) of acquisition and integration-related expenses. That amount includes costs related to its acquisition of Hillrom, primarily reflecting incremental costs of sales from the fair value step-ups on acquired Hillrom inventory that was sold during the period. The acquisition and integration-related expenses related to Hillrom were partially offset by net gains from changes in the estimated fair values of contingent consideration liabilities assumed in the Hillrom acquisition. </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The company's results in 2023 included costs of $16 million ($16 million, or $0.03 per diluted share, on an after-tax basis) of divestiture-related costs, primarily reflecting costs of external advisors supporting its activities to prepare for the proposed spinoff of its Renal Care and Acute Therapies product categories and the pursuit of strategic alternatives (including a potential sale) of its BioPharma Solutions (BPS) product category.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The company&#8217;s results in 2023 and 2022 included costs of $12 million ($9 million, or $0.02 per diluted share, on an&#160;after-tax&#160;basis) and $11 million ($9 million, or $0.02 per diluted share, on an after-tax basis), respectively, of incremental costs to comply with the European Union&#8217;s medical device regulations for previously registered products, which primarily consist of contractor costs and other direct third-party costs. The company considers the adoption of these regulations to be a significant one-</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time regulatory change and believes that the costs of initial compliance for previously registered products over the implementation period are not indicative of its core operating results.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The company's results in 2022 included charges of $23 million ($20 million, or $0.04 per diluted share, on an after-tax basis) related to warranty and remediation activities from two field corrective actions on certain of its infusion pumps.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on the company's use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release.   </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7352449d055545349209a41fc56acfe2_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAXTER &#8212; PAGE 11</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BAXTER INTERNATIONAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales by Operating Segment</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">($ in millions)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:52.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.311%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Growth&#160;&#64;<br>Actual Rates</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Growth&#160;&#64;<br>Constant&#160;Rates</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,602&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,626&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEA</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">APAC</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hillrom</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Baxter</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,649</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,707</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Constant currency growth is a&#160;non-GAAP&#160;measure. For more information on the company&#8217;s use of&#160;non-GAAP&#160;financial measures, please see the Non-GAAP Financial Measures section of this press release.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7352449d055545349209a41fc56acfe2_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAXTER &#8212; PAGE 12</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BAXTER INTERNATIONAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales by Product Category</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">($ in millions)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:52.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.311%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Growth&#160;&#64;<br>Actual Rates</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Growth&#160;&#64;<br>Constant&#160;Rates</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Care&#160;&#185;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medication Delivery&#160;&#178;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals&#160;&#179;</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Nutrition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Surgery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Therapies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioPharma Solutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">7</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient Support Systems </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">8</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Front Line Care </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">9</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Surgical Solutions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">10</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">11</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Baxter</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,649</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,707</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company&#8217;s peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company&#8217;s intravenous (IV)&#160;therapies, infusion pumps, administration sets and drug reconstitution devices.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company&#8217;s premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company&#8217;s parenteral nutrition therapies and related products.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company&#8217;s biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company&#8217;s continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of contracted services the company provides to various pharmaceutical and biopharmaceutical companies.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company's connected care solutions&#58; devices, software, communications and integration technologies and smart beds.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.75pt">Includes sales of the company's integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.5pt">Includes sales of the company's surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. </font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.5pt">Includes sales of other miscellaneous product and service offerings.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Constant currency growth is a&#160;non-GAAP&#160;measure. For more information on the company&#8217;s use of&#160;non-GAAP&#160;financial measures, please see the Non-GAAP Financial Measures section of this press release.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7352449d055545349209a41fc56acfe2_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAXTER &#8212; PAGE 13</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BAXTER INTERNATIONAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Category Sales by U.S. and International</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">($ in millions)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Growth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Renal Care</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">892&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medication Delivery</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">706&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceuticals</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Nutrition</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advanced Surgery</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute Therapies</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioPharma Solutions</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient Support Systems</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Front Line Care</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global Surgical Solutions</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Baxter</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,734</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,915</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,649</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,757</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,950</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,707</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7352449d055545349209a41fc56acfe2_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAXTER &#8212; PAGE 14</font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAXTER INTERNATIONAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of&#160;Non-GAAP&#160;Financial Measure</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Cash Flow to Free Cash Flow</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">($ in millions)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:69.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operations &#8211; continuing operations</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(304)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(372)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(548)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operations - continuing operations</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free cash flow - continuing operations</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Free cash flow is a&#160;non-GAAP&#160;measure. For more information on the company&#8217;s use of&#160;non-GAAP&#160;financial measures, please see the Non-GAAP Financial Measures section of this press release.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7352449d055545349209a41fc56acfe2_37"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAXTER &#8212; PAGE 15</font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAXTER INTERNATIONAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of&#160;Non-GAAP&#160;Financial Measures</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Projected Second Quarter and Full Year 2023 U.S. GAAP Sales Growth to Projected Constant Currency Sales Growth, and Projected Second Quarter and Full Year 2023 U.S. GAAP Earnings Per Share to Projected Adjusted Earnings Per Share</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:61.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales Growth Guidance</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2023*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FY 2023*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales Growth - U.S. GAAP</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1% - 2%</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1% - 2%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1%</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)% - 0%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales Growth - Constant Currency</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2% - 3%</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#126; 1%</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Totals may not foot due to rounding</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings Per Share Guidance</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2023*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FY 2023*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Diluted Share - U.S. GAAP</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$0.18 - $0.20</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1.16 - $1.31</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated intangible asset amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.24</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.96</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated business optimization items</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.02</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.24</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated acquisition and integration items</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.02</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.05</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated divestiture-related costs</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.11</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.36</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated European medical devices regulation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.02</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.08</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Diluted Share - Adjusted</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$0.59- $0.61</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$2.85 - $3.00</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Totals may not foot due to rounding</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The company&#8217;s outlook for U.S. GAAP earnings per share only includes the impact of special items that are known or expected as of the date of this release. Accordingly, actual U.S. GAAP earnings per share for the second quarter and full year of 2023 may differ significantly from those amounts. For example, the company&#8217;s outlook does not reflect the potential impact of future business or asset acquisitions or dispositions (including discontinued operations presentation, if applicable), goodwill or intangible asset impairments, restructuring actions, developments related to gain or loss contingencies, or unusual or infrequently occurring items that may occur during the remainder of 2023.</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bax-20230427.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6253cd8d-ebc9-425e-9b92-f4fbc7470365,g:d94e7b98-a6da-4eb0-ae1e-1ab735b5265d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bax="http://www.baxter.com/20230427" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.baxter.com/20230427">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bax-20230427_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bax-20230427_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bax-20230427_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.baxter.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bax_GlobalNotes13Due2025Member" abstract="true" name="GlobalNotes13Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bax_GlobalNotes04Due2024Member" abstract="true" name="GlobalNotes04Due2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bax_GlobalNotes395Due2030Member" abstract="true" name="GlobalNotes395Due2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bax_GlobalNotes13Due2029Member" abstract="true" name="GlobalNotes13Due2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bax_CommonStock1.00PerValueMember" abstract="true" name="CommonStock1.00PerValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bax_GlobalNotes173Due2031Member" abstract="true" name="GlobalNotes173Due2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>bax-20230427_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6253cd8d-ebc9-425e-9b92-f4fbc7470365,g:d94e7b98-a6da-4eb0-ae1e-1ab735b5265d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.baxter.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="bax-20230427.xsd#DocumentandEntityInformationDocument"/>
  <link:definitionLink xlink:role="http://www.baxter.com/role/DocumentandEntityInformationDocument" xlink:type="extended" id="i48d77c80ab2d44ba80228632ee6f88ee_DocumentandEntityInformationDocument">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_50f75230-4720-4992-aa76-c991e9b73033" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_DocumentType_50f75230-4720-4992-aa76-c991e9b73033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e9f7564b-c54a-4907-aac0-9e2c60804206" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_DocumentPeriodEndDate_e9f7564b-c54a-4907-aac0-9e2c60804206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9c11f4e0-2566-4c27-a28f-53a5df99fbe0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityRegistrantName_9c11f4e0-2566-4c27-a28f-53a5df99fbe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bf5b0f05-496e-4187-bc23-9f8bac564a34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityCentralIndexKey_bf5b0f05-496e-4187-bc23-9f8bac564a34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_00c32806-9886-4dcf-86c3-257f70256b8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_AmendmentFlag_00c32806-9886-4dcf-86c3-257f70256b8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b24d1096-b6b8-4764-9869-b4e32bc5bdf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b24d1096-b6b8-4764-9869-b4e32bc5bdf7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e41577d9-c06c-4bff-bcb9-dfdf76f1495e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityFileNumber_e41577d9-c06c-4bff-bcb9-dfdf76f1495e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_71862c3c-fcaa-4d3a-bc60-c193601fd142" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityTaxIdentificationNumber_71862c3c-fcaa-4d3a-bc60-c193601fd142" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6abb5786-4389-411e-a6f6-a807322f8201" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressAddressLine1_6abb5786-4389-411e-a6f6-a807322f8201" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_71829fc1-c21b-4285-af4e-ffb59fa1da02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressCityOrTown_71829fc1-c21b-4285-af4e-ffb59fa1da02" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_18e3b202-5d8c-4c5a-b866-d625a27e28e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressStateOrProvince_18e3b202-5d8c-4c5a-b866-d625a27e28e0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c632f69c-fd47-4ba3-aa18-11b563308efb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressPostalZipCode_c632f69c-fd47-4ba3-aa18-11b563308efb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1885bd35-0a4a-44c1-850e-f1766f52395e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_CityAreaCode_1885bd35-0a4a-44c1-850e-f1766f52395e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dd1a9438-c004-4ba9-9ce1-ea50beeac41f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_LocalPhoneNumber_dd1a9438-c004-4ba9-9ce1-ea50beeac41f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9d05f1df-826f-44b6-ad35-bd66a3bdc0f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_WrittenCommunications_9d05f1df-826f-44b6-ad35-bd66a3bdc0f9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_36dcb41d-93db-4997-868a-53156a3ab73f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_SolicitingMaterial_36dcb41d-93db-4997-868a-53156a3ab73f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d45e4aaf-5219-487f-a12d-456f64295fb1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_PreCommencementTenderOffer_d45e4aaf-5219-487f-a12d-456f64295fb1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_58cdcf11-db39-4acb-83a4-ec261d84a913" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_58cdcf11-db39-4acb-83a4-ec261d84a913" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1a278f3b-1967-474f-a800-d88a9fcc1c59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityEmergingGrowthCompany_1a278f3b-1967-474f-a800-d88a9fcc1c59" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_22bbfee2-c8f0-4530-8a18-906edb7660df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_Security12bTitle_22bbfee2-c8f0-4530-8a18-906edb7660df" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1f90b8ac-87c1-46cb-83f0-fe5e4d37e03b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_TradingSymbol_1f90b8ac-87c1-46cb-83f0-fe5e4d37e03b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_58c0397b-3fb3-4380-88af-5b2147228d34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_SecurityExchangeName_58c0397b-3fb3-4380-88af-5b2147228d34" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:to="loc_dei_EntityListingsExchangeAxis_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1" xlink:to="loc_dei_ExchangeDomain_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1" xlink:to="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_2485d50d-9557-4a14-a808-eb8306a1197f" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:to="loc_exch_XNYS_2485d50d-9557-4a14-a808-eb8306a1197f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_6963a4d2-ad8e-4bcd-aade-f357be915537" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XCHI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:to="loc_exch_XCHI_6963a4d2-ad8e-4bcd-aade-f357be915537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9c5d7efc-8c2b-452f-97f3-4d8183383589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9c5d7efc-8c2b-452f-97f3-4d8183383589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9c5d7efc-8c2b-452f-97f3-4d8183383589_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c5d7efc-8c2b-452f-97f3-4d8183383589" xlink:to="loc_us-gaap_ClassOfStockDomain_9c5d7efc-8c2b-452f-97f3-4d8183383589_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c5d7efc-8c2b-452f-97f3-4d8183383589" xlink:to="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_CommonStock1.00PerValueMember_4aac1c9c-da4b-4e70-8eb9-0a08ae36a980" xlink:href="bax-20230427.xsd#bax_CommonStock1.00PerValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_CommonStock1.00PerValueMember_4aac1c9c-da4b-4e70-8eb9-0a08ae36a980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes13Due2025Member_dbc0ee16-ae99-4f4d-9335-d0ecc1a4cd51" xlink:href="bax-20230427.xsd#bax_GlobalNotes13Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes13Due2025Member_dbc0ee16-ae99-4f4d-9335-d0ecc1a4cd51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes13Due2029Member_e20ebc39-3cd7-4440-a980-66ae0655f3b7" xlink:href="bax-20230427.xsd#bax_GlobalNotes13Due2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes13Due2029Member_e20ebc39-3cd7-4440-a980-66ae0655f3b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes04Due2024Member_6e26706f-527b-45a0-93de-ac792cb61541" xlink:href="bax-20230427.xsd#bax_GlobalNotes04Due2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes04Due2024Member_6e26706f-527b-45a0-93de-ac792cb61541" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes395Due2030Member_d88040d9-d317-49d8-a555-309b262e14f4" xlink:href="bax-20230427.xsd#bax_GlobalNotes395Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes395Due2030Member_d88040d9-d317-49d8-a555-309b262e14f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes173Due2031Member_f49cf00e-89a9-436e-9bfe-dd98d6556c0c" xlink:href="bax-20230427.xsd#bax_GlobalNotes173Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes173Due2031Member_f49cf00e-89a9-436e-9bfe-dd98d6556c0c" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bax-20230427_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6253cd8d-ebc9-425e-9b92-f4fbc7470365,g:d94e7b98-a6da-4eb0-ae1e-1ab735b5265d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_33d327f8-0a6e-4bb1-941b-52faed06aa7a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_56542a3e-3d3a-4e20-897c-4142a39eafc2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_de13e8b8-95c4-4678-8264-279c9201679b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f12f9e23-d5b3-4d8e-b7bb-639e1c96d119_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_7e12f29e-40c3-4d98-967a-6760a72bc0a8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_79eca8db-2bcc-4da9-9679-f0eb9e360c1e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9c400152-7ae5-4211-9814-48a94fe2cf7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bax_GlobalNotes395Due2030Member_914ff2e0-e65d-4317-8f3a-827fe91a3977_terseLabel_en-US" xlink:label="lab_bax_GlobalNotes395Due2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 3.95% due 2030</link:label>
    <link:label id="lab_bax_GlobalNotes395Due2030Member_label_en-US" xlink:label="lab_bax_GlobalNotes395Due2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 3.95% due 2030 [Member]</link:label>
    <link:label id="lab_bax_GlobalNotes395Due2030Member_documentation_en-US" xlink:label="lab_bax_GlobalNotes395Due2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 3.95% due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes395Due2030Member" xlink:href="bax-20230427.xsd#bax_GlobalNotes395Due2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bax_GlobalNotes395Due2030Member" xlink:to="lab_bax_GlobalNotes395Due2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2978d078-8050-4607-857d-e25c050d66e2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bax_GlobalNotes04Due2024Member_74243c6c-c4ad-4658-a5c9-ee2985e5bf95_terseLabel_en-US" xlink:label="lab_bax_GlobalNotes04Due2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.4% Global Notes due 2024</link:label>
    <link:label id="lab_bax_GlobalNotes04Due2024Member_label_en-US" xlink:label="lab_bax_GlobalNotes04Due2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 0.4% due 2024 [Member]</link:label>
    <link:label id="lab_bax_GlobalNotes04Due2024Member_documentation_en-US" xlink:label="lab_bax_GlobalNotes04Due2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.4% Global Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes04Due2024Member" xlink:href="bax-20230427.xsd#bax_GlobalNotes04Due2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bax_GlobalNotes04Due2024Member" xlink:to="lab_bax_GlobalNotes04Due2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5de423ee-e6f9-4721-9b18-5a26d5a78159_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_45369caa-0bec-4e81-85be-6149173b4909_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dd93d34a-18c3-4816-b902-0f0f235c565d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_47a0f9c3-c8e2-4900-97a7-26abf2d674bb_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bax_GlobalNotes13Due2025Member_d4d6fc33-e5fc-4ab2-8c3f-99baecc21c85_terseLabel_en-US" xlink:label="lab_bax_GlobalNotes13Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.3% Global Notes due 2025</link:label>
    <link:label id="lab_bax_GlobalNotes13Due2025Member_label_en-US" xlink:label="lab_bax_GlobalNotes13Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 1.3% due 2025 [Member]</link:label>
    <link:label id="lab_bax_GlobalNotes13Due2025Member_documentation_en-US" xlink:label="lab_bax_GlobalNotes13Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.3% Global Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes13Due2025Member" xlink:href="bax-20230427.xsd#bax_GlobalNotes13Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bax_GlobalNotes13Due2025Member" xlink:to="lab_bax_GlobalNotes13Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c087b371-3131-4e4d-a1a0-c402dc55d61d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XCHI_b01f1cc5-be44-44f7-a338-7e7af9ae2023_terseLabel_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC</link:label>
    <link:label id="lab_exch_XCHI_label_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NYSE CHICAGO, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XCHI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XCHI" xlink:to="lab_exch_XCHI" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_c9930369-ebb6-4734-ad33-5c97aa40ce66_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_829c20f6-319d-4b58-be65-097cab9f0a3d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b894cf1d-23c2-4aed-b54f-fa40f33c013b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c824ea29-be9e-49bf-941d-dbde5736ddb7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bax_GlobalNotes173Due2031Member_453eb471-a564-44c9-b67b-1bc62ce11ad8_terseLabel_en-US" xlink:label="lab_bax_GlobalNotes173Due2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 1.73% due 2031</link:label>
    <link:label id="lab_bax_GlobalNotes173Due2031Member_label_en-US" xlink:label="lab_bax_GlobalNotes173Due2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 1.73% due 2031 [Member]</link:label>
    <link:label id="lab_bax_GlobalNotes173Due2031Member_documentation_en-US" xlink:label="lab_bax_GlobalNotes173Due2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 1.73% due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes173Due2031Member" xlink:href="bax-20230427.xsd#bax_GlobalNotes173Due2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bax_GlobalNotes173Due2031Member" xlink:to="lab_bax_GlobalNotes173Due2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_2afa5c7a-a2c1-4b55-9e09-7153dd99458a_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_abe7f707-d616-47cd-8afc-fd9c725faedc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bax_CommonStock1.00PerValueMember_8ee78b7f-9b19-4ad4-8eb2-41cc552c88f2_terseLabel_en-US" xlink:label="lab_bax_CommonStock1.00PerValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $1.00 Per Value</link:label>
    <link:label id="lab_bax_CommonStock1.00PerValueMember_label_en-US" xlink:label="lab_bax_CommonStock1.00PerValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $1.00 Per Value [Member]</link:label>
    <link:label id="lab_bax_CommonStock1.00PerValueMember_documentation_en-US" xlink:label="lab_bax_CommonStock1.00PerValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $1.00 Per Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bax_CommonStock1.00PerValueMember" xlink:href="bax-20230427.xsd#bax_CommonStock1.00PerValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bax_CommonStock1.00PerValueMember" xlink:to="lab_bax_CommonStock1.00PerValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_6c17e225-b857-4cc2-a368-13e4177d9b38_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4d6be33c-ccce-4851-8810-04e62e2e357c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bax_GlobalNotes13Due2029Member_cd849adc-3093-43af-9030-5ba3ffe000ff_terseLabel_en-US" xlink:label="lab_bax_GlobalNotes13Due2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.3% Global Notes due 2029</link:label>
    <link:label id="lab_bax_GlobalNotes13Due2029Member_label_en-US" xlink:label="lab_bax_GlobalNotes13Due2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Notes 1.3% due 2029 [Member]</link:label>
    <link:label id="lab_bax_GlobalNotes13Due2029Member_documentation_en-US" xlink:label="lab_bax_GlobalNotes13Due2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.3% Global Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes13Due2029Member" xlink:href="bax-20230427.xsd#bax_GlobalNotes13Due2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bax_GlobalNotes13Due2029Member" xlink:to="lab_bax_GlobalNotes13Due2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7224d6be-6d29-497d-93c8-df29ffa9b998_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bf536330-1612-45c0-a870-cf1c68b065cb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_272736b0-a8e0-44ea-bd30-f54c4ede6fef_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c2e4ec10-a7c6-4fa6-9ad5-8daa5372674d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_e59c5806-94c1-41ee-8ba9-a4b1c3c3eb43_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC.</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f4720895-e70f-46e6-a31b-4e6f8e68884e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5ccea8e1-50ca-4169-92e0-2d19bc2f2226_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5bf1431b-fc64-4f12-9bdf-bec1a8ee0593_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0ca703ac-6263-4fc2-985a-82df71bef467_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bax-20230427_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6253cd8d-ebc9-425e-9b92-f4fbc7470365,g:d94e7b98-a6da-4eb0-ae1e-1ab735b5265d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.baxter.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="bax-20230427.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.baxter.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e6f2256c-d85c-4f4d-8242-eee5ce62ce71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e6f2256c-d85c-4f4d-8242-eee5ce62ce71" xlink:to="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:to="loc_dei_EntityListingsExchangeAxis_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_2ebc4254-c5ed-408f-81c7-8e262fe8ebc1" xlink:to="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_2485d50d-9557-4a14-a808-eb8306a1197f" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:to="loc_exch_XNYS_2485d50d-9557-4a14-a808-eb8306a1197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_6963a4d2-ad8e-4bcd-aade-f357be915537" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XCHI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_c031a1fb-6b10-4fe7-a42f-754aac24dac4" xlink:to="loc_exch_XCHI_6963a4d2-ad8e-4bcd-aade-f357be915537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9c5d7efc-8c2b-452f-97f3-4d8183383589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9c5d7efc-8c2b-452f-97f3-4d8183383589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c5d7efc-8c2b-452f-97f3-4d8183383589" xlink:to="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_CommonStock1.00PerValueMember_4aac1c9c-da4b-4e70-8eb9-0a08ae36a980" xlink:href="bax-20230427.xsd#bax_CommonStock1.00PerValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_CommonStock1.00PerValueMember_4aac1c9c-da4b-4e70-8eb9-0a08ae36a980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes13Due2025Member_dbc0ee16-ae99-4f4d-9335-d0ecc1a4cd51" xlink:href="bax-20230427.xsd#bax_GlobalNotes13Due2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes13Due2025Member_dbc0ee16-ae99-4f4d-9335-d0ecc1a4cd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes13Due2029Member_e20ebc39-3cd7-4440-a980-66ae0655f3b7" xlink:href="bax-20230427.xsd#bax_GlobalNotes13Due2029Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes13Due2029Member_e20ebc39-3cd7-4440-a980-66ae0655f3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes04Due2024Member_6e26706f-527b-45a0-93de-ac792cb61541" xlink:href="bax-20230427.xsd#bax_GlobalNotes04Due2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes04Due2024Member_6e26706f-527b-45a0-93de-ac792cb61541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes395Due2030Member_d88040d9-d317-49d8-a555-309b262e14f4" xlink:href="bax-20230427.xsd#bax_GlobalNotes395Due2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes395Due2030Member_d88040d9-d317-49d8-a555-309b262e14f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bax_GlobalNotes173Due2031Member_f49cf00e-89a9-436e-9bfe-dd98d6556c0c" xlink:href="bax-20230427.xsd#bax_GlobalNotes173Due2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf8bb7a0-9ccb-4d6c-9ff9-254ca0774d16" xlink:to="loc_bax_GlobalNotes173Due2031Member_f49cf00e-89a9-436e-9bfe-dd98d6556c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_fd24a7f6-478e-48d4-bbdb-511f480c0f36" xlink:to="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_50f75230-4720-4992-aa76-c991e9b73033" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_DocumentType_50f75230-4720-4992-aa76-c991e9b73033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e9f7564b-c54a-4907-aac0-9e2c60804206" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_DocumentPeriodEndDate_e9f7564b-c54a-4907-aac0-9e2c60804206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9c11f4e0-2566-4c27-a28f-53a5df99fbe0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityRegistrantName_9c11f4e0-2566-4c27-a28f-53a5df99fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bf5b0f05-496e-4187-bc23-9f8bac564a34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityCentralIndexKey_bf5b0f05-496e-4187-bc23-9f8bac564a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_00c32806-9886-4dcf-86c3-257f70256b8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_AmendmentFlag_00c32806-9886-4dcf-86c3-257f70256b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b24d1096-b6b8-4764-9869-b4e32bc5bdf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b24d1096-b6b8-4764-9869-b4e32bc5bdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e41577d9-c06c-4bff-bcb9-dfdf76f1495e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityFileNumber_e41577d9-c06c-4bff-bcb9-dfdf76f1495e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_71862c3c-fcaa-4d3a-bc60-c193601fd142" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityTaxIdentificationNumber_71862c3c-fcaa-4d3a-bc60-c193601fd142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6abb5786-4389-411e-a6f6-a807322f8201" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressAddressLine1_6abb5786-4389-411e-a6f6-a807322f8201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_71829fc1-c21b-4285-af4e-ffb59fa1da02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressCityOrTown_71829fc1-c21b-4285-af4e-ffb59fa1da02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_18e3b202-5d8c-4c5a-b866-d625a27e28e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressStateOrProvince_18e3b202-5d8c-4c5a-b866-d625a27e28e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c632f69c-fd47-4ba3-aa18-11b563308efb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityAddressPostalZipCode_c632f69c-fd47-4ba3-aa18-11b563308efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1885bd35-0a4a-44c1-850e-f1766f52395e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_CityAreaCode_1885bd35-0a4a-44c1-850e-f1766f52395e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dd1a9438-c004-4ba9-9ce1-ea50beeac41f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_LocalPhoneNumber_dd1a9438-c004-4ba9-9ce1-ea50beeac41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9d05f1df-826f-44b6-ad35-bd66a3bdc0f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_WrittenCommunications_9d05f1df-826f-44b6-ad35-bd66a3bdc0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_36dcb41d-93db-4997-868a-53156a3ab73f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_SolicitingMaterial_36dcb41d-93db-4997-868a-53156a3ab73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d45e4aaf-5219-487f-a12d-456f64295fb1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_PreCommencementTenderOffer_d45e4aaf-5219-487f-a12d-456f64295fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_58cdcf11-db39-4acb-83a4-ec261d84a913" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_58cdcf11-db39-4acb-83a4-ec261d84a913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1a278f3b-1967-474f-a800-d88a9fcc1c59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_EntityEmergingGrowthCompany_1a278f3b-1967-474f-a800-d88a9fcc1c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_22bbfee2-c8f0-4530-8a18-906edb7660df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_Security12bTitle_22bbfee2-c8f0-4530-8a18-906edb7660df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1f90b8ac-87c1-46cb-83f0-fe5e4d37e03b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_TradingSymbol_1f90b8ac-87c1-46cb-83f0-fe5e4d37e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_58c0397b-3fb3-4380-88af-5b2147228d34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_08fc4893-6733-4d44-9a3a-7d4a97779c65" xlink:to="loc_dei_SecurityExchangeName_58c0397b-3fb3-4380-88af-5b2147228d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g782573page6aa01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g782573page6aa01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M&#Q%<7LCV!@M+7)\M#$';';)/?Z5VPP%)+WM6<4\=4;]W1&P==^* T+^VBL
ML?)\_<4BSLQG.WKTYK'V6$Y^3K\S;VF*Y.?I\C'TWXP^(K:\C>_\B[MLC>GE
MA&QWP1W^M;3P%)KW=&8PQU1/WM4;_P 0?B'K&B>(TL]'ND2#[.CNKQ*V&;)[
M^V*PPN$A4I\TT;XG%3ISM!F/IWQ&\=:I:S0V%J;R=6!,L5KN\M?3 &.?>M9X
M3#P=Y.WS,H8JO-6BK_(ZOP-K?C74_$;V^O1/;VD4!D*R6OEEB3@8./K^5<N)
MIX>%.]/?U.G#U*\IVJ;>AZ37G'H' ?%_5/L/@W[(K8DO9ECQ_LCYC_(#\:[\
M!#FJW['#CI\M*W<\*TVR?4M4M+&+[]Q*L0_$XKVYR4(N3Z'C0CS244>O^+_A
M[X5\/^$[_48H)A/%'B(F=C\Y( X^IKR</BZU6HHMGJU\+2ITW*QXS&\D4J/"
MS+(I!1E."#VQ7L-)JS/(6CT/0OB+XMUK^TX='6^DA6UMXQ<"%BGF2E06)(^O
M2N#"4*?+SVWV]#OQ5>?-R7V(?!'A35O&-M=W!UZYM(8'" [F?<V,G^(8P,?G
M3Q->%!I<MQ8>C.LF^:QS?BO3WTGQ'<Z:^H27YML(9I,@YP"1R3TS730GSTU*
MUKG-7CR3<;WL>A_!'3/GU356' "VZ'_QYO\ V6O/S&?PP^9WY?#>1U/Q2@TB
M?PA*NI7*03H=]H3RQD'8#J0>A_.N7!.:J^ZM.ITXQ0=/WGZ'SS7T!X)] ?"<
M:-)X42;3K98KQ3Y=VQ.7+COGT(Y Z5X&.]HJEI/3H>[@N3V=XK7J>?\ Q@U,
MWOC(6:GY+*%4Q_M-\Q_0C\J]# 0Y:5^YPXZ=ZENQL?!+3-]YJ>JLO$:+ A]S
MRW\E_.L<QG91@:Y?#5S.W^)>I_V9X$U J</< 6Z_\"//Z9KBP<.>LO+4[,7/
MDI,^=[&RGU&^@LK9-\\[B-%SC))Q7T$I*$7)]#P8Q<I**/5[K1/BC>:2^ES2
MVILWC\HHIC7Y>F,@9KRHU,'&7.M_F>HZ>*<>5[?(P;#X2>)/[1MOMEO EKYJ
M^:PG!(3//'TKHECJ7*^5ZF$<%4YE?8Y7Q1J7]K^*-2OE.4EG;R_]P<+^@%=-
M"')343FK3YZCD>U_"/3?L/@B.X9</>2M+^ ^4?\ H/ZUXV/GS5K=CU\%#EI7
M[G>5PG:% 'FGQ'\(>(O%FJ6OV%+<65K&0IDFP69NIQCV KTL)7I4(OFW9Y^*
MH5*TER[(X^V^%'C&SN([BVDMH9HSE)$N"&4^H.*ZWCJ$E9_D<BP5:+NBW??#
MWX@ZG"(;_4EN8@=P26\9AGUP141Q>&@[Q5OD7+"XB2M)_B2^'?A#J\6N6L^K
M/;)9P.)&6-][/@Y"]*57'P<&H;CI8&:FG/8T_'7POU'6=?EU72)H6^TX,L4S
M%2K 8R#CD<5GAL;&G#DGT-,3@Y3GSP*>B^#OB/H%JUIIE_:6T#OO9=ZL,\#/
M*GT%54Q&%J.\DV33H8FFK1=C+OOA-XMN=0N)Y)K6X>21F,K2X+DGKC'&:UCC
MJ*BDM#*6"K.3;/0/#FBZ]X5\#1Z?8V5M+JID=F,DV(P2>&SC)XQQ^M<%:I3K
M5N:3T.ZE3J4:7+%:F+IGPTU+6-9?5?&E\+EP?E@B<D$>A/&%]A6T\9"G#DH*
MQE#"2G+FK.Y1\8_"B]O=>:Z\/Q6T5I*@+1,VP(_0X '3H?SK3#XZ,86J;F=?
M!.4[T]BSX#\%^*_"6O">5;9K&<;+A%FR<=F QU!_F:G$XBC6A9;K8K#8>K1G
M=[">//ACJ>M^(9=6TJ:%A<!?,CE8J58 #(..1@"C#8R%.')/H&)P<JD^>/4J
MZ%X1^(_AJWEM]+NK*&&1M[(SJXW8QGE?:JJU\+5=YIDTZ&)I*T6;UWX/\2>)
MO"-S9>(=2B.I?:%EMRH'EH%7&#M ZY;]*PCB*5*JI4UI8VE0JU:;C4>IQ=C\
M+?&6F7\-[9O9QW$#[HW$V<$>Q%=DL;0G'EE>QR1P=:#NCJ_LOQ9_Z"&G_DG_
M ,37+S8+LSJY<7W1>L;'XAM:Z@=4O;660V[1VT49509&XW,0O11DX]:B4L-=
M<BZZEQCB+/F9Y]_PI_Q4!]VS_P"__P#]:N_Z_1\S@^HU3W'0[#^R]!L+':%-
MO D; '(R ,_K7BU)<\W+N>S3CR04>Q?K,L* "@ H * "@ H * "@ H * "@
5H * "@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139766486581760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 27,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Baxter International Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000010456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-4448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-0781620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Baxter Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Deerfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">948-2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | Common Stock, $1.00 Per Value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $1.00 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BAX (NYSE)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | 1.3% Global Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.3% Global Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BAX 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | 1.3% Global Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.3% Global Notes due 2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BAX 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC. | 0.4% Global Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.4% Global Notes due 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BAX 24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XCHI', window );">CHICAGO STOCK EXCHANGE, INC | Common Stock, $1.00 Per Value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $1.00 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BAX (NYSE)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">CHX<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bax_CommonStock1.00PerValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bax_CommonStock1.00PerValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bax_GlobalNotes13Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bax_GlobalNotes13Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bax_GlobalNotes13Due2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bax_GlobalNotes13Due2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bax_GlobalNotes04Due2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bax_GlobalNotes04Due2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XCHI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XCHI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>bax-20230427_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bax="http://www.baxter.com/20230427"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exch="http://xbrl.sec.gov/exch/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bax-20230427.xsd" xlink:type="simple"/>
    <context id="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000010456</identifier>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000010456</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:CommonStock1.00PerValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000010456</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:CommonStock1.00PerValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="icea79023a6fe4549954e7859fe72a386_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000010456</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:GlobalNotes04Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000010456</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:GlobalNotes13Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i2a12f6738785458cba103994ca1398b5_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000010456</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bax:GlobalNotes13Due2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl80L2ZyYWc6ZTBhZWNkMWM2ZGZhNGUxMGE1NTc0MjBjYTdlNzg4YjYvdGFibGU6NzZjOGMzNTA5NGVhNGQyZGFmNDZmM2NmNWFmMTZjOTAvdGFibGVyYW5nZTo3NmM4YzM1MDk0ZWE0ZDJkYWY0NmYzY2Y1YWYxNmM5MF8yLTEtMS0xLTE0MjYyMg_21ad4116-4b4f-42e8-88e2-8415609889c5">0000010456</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl80L2ZyYWc6ZTBhZWNkMWM2ZGZhNGUxMGE1NTc0MjBjYTdlNzg4YjYvdGFibGU6NzZjOGMzNTA5NGVhNGQyZGFmNDZmM2NmNWFmMTZjOTAvdGFibGVyYW5nZTo3NmM4YzM1MDk0ZWE0ZDJkYWY0NmYzY2Y1YWYxNmM5MF8zLTEtMS0xLTE0MjYyMg_6cf0552a-e447-469e-9268-c34348567890">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl84Mg_2633f316-2b96-49c3-bc17-8cc643124381">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl8yMjM_03a9874a-684c-4f2e-8095-670245a9146b">2023-04-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8wLTAtMS0xLTE0MjYyMg_d31d9a6e-70c0-4b65-ae17-5fcc0f56e38e">Baxter International Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8zLTAtMS0xLTE0MjYyMg_1f7762c6-67f1-4007-9c68-87293dac9949">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV82LTAtMS0xLTE0MjYyMg_f7e2a50b-b5c1-4615-aa19-252e413341d3">1-4448</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV82LTEtMS0xLTE0MjYyMg_673fc011-38e4-453b-9e43-1304896a0b4e">36-0781620</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTAtMS0xLTE0MjYyMi90ZXh0cmVnaW9uOmIxMGExNjQ1NGYxOTRkNGFiYTBiN2JlODEwNmM5Nzk5XzQ_4fad1adf-cb94-4837-802f-71f1660b6be8">One Baxter Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTAtMS0xLTE0MjYyMi90ZXh0cmVnaW9uOmIxMGExNjQ1NGYxOTRkNGFiYTBiN2JlODEwNmM5Nzk5Xzg_ae9c2d7a-3981-4987-9ed0-083f6c10466f">Deerfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTAtMS0xLTE0MjYyMi90ZXh0cmVnaW9uOmIxMGExNjQ1NGYxOTRkNGFiYTBiN2JlODEwNmM5Nzk5XzEy_a3cc51aa-c741-407d-9dad-bcaa444f5995">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV85LTEtMS0xLTE0MjYyMg_25bd04c4-b7c2-4676-ba26-540de678af0a">60015</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8xMi0wLTEtMS0xNDI2MjIvdGV4dHJlZ2lvbjoyYzFlNDQ0MDk4Nzk0ZTgxYjAzYjkwNTgxYWZmNmJkNl81_d0d3399d-3c3f-4775-b98b-82a18cff76c0">224</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6MTAxNTYwNTEyYjNhNDc4NmFmNWEwMjIxNDM3NDg4MmEvdGFibGVyYW5nZToxMDE1NjA1MTJiM2E0Nzg2YWY1YTAyMjE0Mzc0ODgyYV8xMi0wLTEtMS0xNDI2MjIvdGV4dHJlZ2lvbjoyYzFlNDQ0MDk4Nzk0ZTgxYjAzYjkwNTgxYWZmNmJkNl84_9422a04e-1303-409c-85fa-6d485c3527e8">948-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl8zOTk_cbb5f40e-71bb-4e28-8322-95f21341208c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl80OTE_5fbf76df-fe32-4d1b-baf8-b73165128f8c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl81ODQ_863bcac9-1334-4890-bcf7-a0b3cad6a3a6">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl82OTM_1d120f88-ebc6-4e67-ac24-c1a07a1cb7ac">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTAtMS0xLTE0MjYyMg_74de5d99-984c-4081-b331-6c670b434742">Common Stock, $1.00 par value</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTAtMS0xLTE0MjYyMg_d5d672e7-a625-4d69-9520-a7b29872f601">Common Stock, $1.00 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTItMS0xLTE0MjYyMg_0ed05bdf-d5b6-4bb1-a2de-17e52d3ab8bb">BAX (NYSE)</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTItMS0xLTE0MjYyMg_29d1994e-faa1-45ed-bb00-b785c58442bf">BAX (NYSE)</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iad2e864893dd41f1a715067bddaa92cb_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8xLTQtMS0xLTE0MjYyMg_5bc9343f-c65b-40b6-95cf-1a4cf0bd8947">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="i7c705700df9d4f088551d75dac3a53f5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8yLTQtMS0xLTE0MjYyMg_d808e90d-e9fb-46c4-ab23-1728e11ba517">CHX</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="icea79023a6fe4549954e7859fe72a386_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTAtMS0xLTE2MTE2MQ_ffe09d41-47dd-4edb-8897-6d5781564f56">0.4% Global Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icea79023a6fe4549954e7859fe72a386_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTItMS0xLTE2MTE2MQ_a025aa46-b4ad-4070-9207-0bc7a962f586">BAX 24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icea79023a6fe4549954e7859fe72a386_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTQtMS0xLTE2MTE2MQ_59b966bf-8fb4-4588-92ee-2a01f59349f4">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTAtMS0xLTE0MjYyMg_1895d223-d635-4795-9117-4f6402312acb">1.3% Global Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTItMS0xLTE0MjYyMg_fe0bef07-9d94-499f-bdfe-a0abd135d04d">BAX 25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i87656bdb60cf49bb861a35a609ba959e_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl8zLTQtMS0xLTE0MjYyMg_98e67e43-bf45-444f-91eb-4cdd50cf1314">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2a12f6738785458cba103994ca1398b5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl80LTAtMS0xLTE0MjYyMg_4cc76c65-4fde-43d8-9aea-bb38aae8cd63">1.3% Global Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2a12f6738785458cba103994ca1398b5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl80LTItMS0xLTE0MjYyMg_258a40dd-f1f1-4d21-8e8f-0b325df0d0cc">BAX 29</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2a12f6738785458cba103994ca1398b5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGFibGU6NzQ1YzgxNWIzMjYzNDVhMGJlZTk5YTg4NDM3Yzk2ZWIvdGFibGVyYW5nZTo3NDVjODE1YjMyNjM0NWEwYmVlOTlhODg0MzdjOTZlYl80LTQtMS0xLTE0MjYyMg_564886d4-030f-417a-8660-056821460620">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl8xL2ZyYWc6OThiZmUxYmE2MDUyNGUyMWE4YzhhZWFlOGY5YTU4NjYvdGV4dHJlZ2lvbjo5OGJmZTFiYTYwNTI0ZTIxYThjOGFlYWU4ZjlhNTg2Nl8xMTAy_0641c141-89aa-4b13-b24f-a26e5fb98c29">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="id066745f3c1a418280cd16cc8b644c27_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDUwMjI2OTRiYTQ0YzhhNmQ1NzkyM2JhMGFmMDJiL3NlYzo5ZTQ1MDIyNjk0YmE0NGM4YTZkNTc5MjNiYTBhZjAyYl83L2ZyYWc6Njk0MWY5NmFhYTIxNDgwMTgwYjUxMjVjOTE5NjliZjQvdGV4dHJlZ2lvbjo2OTQxZjk2YWFhMjE0ODAxODBiNTEyNWM5MTk2OWJmNF81NDk3NTU4MTQxNDM_03a9874a-684c-4f2e-8095-670245a9146b">2023-04-27</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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M\/N$@[VM=M3[U^KU>?L_4$L#!!0    ( %LZFU:?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( %LZFU8'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 6SJ;
M5GI[H?WP    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ 6SJ;5IE<G",0!@  G"<  !,              ( !
MS@$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !;.IM68HK"_JT%
M  !*'P  &               @($/"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ 6SJ;5I^@&_"Q @  X@P   T              ( !
M\@T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !;.IM6EXJ[',     3 @
M"P              @ '.$   7W)E;',O+G)E;'-02P$"% ,4    " !;.IM6
M'#AEZC\!   \ @  #P              @ &W$0  >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ 6SJ;5B0>FZ*M    ^ $  !H              ( !(Q,
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 6SJ;5F60
M>9(9 0  SP,  !,              ( !"!0  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  4A4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>6</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>6</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bax-20230427.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.baxter.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="bax-20230427.htm">bax-20230427.htm</File>
    <File>bax-20230331xex991.htm</File>
    <File>bax-20230427.xsd</File>
    <File>bax-20230427_def.xml</File>
    <File>bax-20230427_lab.xml</File>
    <File>bax-20230427_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bax-20230427.htm": {
   "axisCustom": 0,
   "axisStandard": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 35
   },
   "contextCount": 6,
   "dts": {
    "definitionLink": {
     "local": [
      "bax-20230427_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bax-20230427.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bax-20230427_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bax-20230427_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bax-20230427.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd"
     ]
    }
   },
   "elementCount": 37,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 4,
   "memberStandard": 2,
   "nsprefix": "bax",
   "nsuri": "http://www.baxter.com/20230427",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bax-20230427.htm",
      "contextRef": "id066745f3c1a418280cd16cc8b644c27_D20230427-20230427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.baxter.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bax-20230427.htm",
      "contextRef": "id066745f3c1a418280cd16cc8b644c27_D20230427-20230427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 6,
   "tag": {
    "bax_CommonStock1.00PerValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, $1.00 Per Value [Member]",
        "label": "Common Stock, $1.00 Per Value [Member]",
        "terseLabel": "Common Stock, $1.00 Per Value"
       }
      }
     },
     "localname": "CommonStock1.00PerValueMember",
     "nsuri": "http://www.baxter.com/20230427",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "bax_GlobalNotes04Due2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.4% Global Notes due 2024 [Member]",
        "label": "Global Notes 0.4% due 2024 [Member]",
        "terseLabel": "0.4% Global Notes due 2024"
       }
      }
     },
     "localname": "GlobalNotes04Due2024Member",
     "nsuri": "http://www.baxter.com/20230427",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "bax_GlobalNotes13Due2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.3% Global Notes due 2025 [Member]",
        "label": "Global Notes 1.3% due 2025 [Member]",
        "terseLabel": "1.3% Global Notes due 2025"
       }
      }
     },
     "localname": "GlobalNotes13Due2025Member",
     "nsuri": "http://www.baxter.com/20230427",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "bax_GlobalNotes13Due2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.3% Global Notes due 2029 [Member]",
        "label": "Global Notes 1.3% due 2029 [Member]",
        "terseLabel": "1.3% Global Notes due 2029"
       }
      }
     },
     "localname": "GlobalNotes13Due2029Member",
     "nsuri": "http://www.baxter.com/20230427",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "bax_GlobalNotes173Due2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Notes 1.73% due 2031",
        "label": "Global Notes 1.73% due 2031 [Member]",
        "terseLabel": "Global Notes 1.73% due 2031"
       }
      }
     },
     "localname": "GlobalNotes173Due2031Member",
     "nsuri": "http://www.baxter.com/20230427",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "bax_GlobalNotes395Due2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Notes 3.95% due 2030",
        "label": "Global Notes 3.95% due 2030 [Member]",
        "terseLabel": "Global Notes 3.95% due 2030"
       }
      }
     },
     "localname": "GlobalNotes395Due2030Member",
     "nsuri": "http://www.baxter.com/20230427",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "exch_XCHI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NYSE CHICAGO, INC. [Member]",
        "terseLabel": "CHICAGO STOCK EXCHANGE, INC"
       }
      }
     },
     "localname": "XCHI",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "NEW YORK STOCK EXCHANGE, INC."
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.baxter.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-013356-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-013356-xbrl.zip
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M,JZ:304PQ8J%8I@].R>0 VNR3>F[22;#>Z;A6X,WDJ/S/EC<S!!HEHDR\5H
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MO' "\QZN;2&,8P0IK*F)OR)61)4=F .^VHQ\'P,D]G3FL"E\HO%L*7&!8#P
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M%@+[( N!%7[FJD! X0H$M'IE.<I_L (!K=[^:R2H @&J0( J$* *!*@" :I
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M6Z%]=T=*[ <5@\%K;Z/9S//A_WD0LFE RJ<!G=72P]5J*Q?,(<%[=IRLFYJ
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MS]VSAPIS(/3MT+/F\-\DG#J__?]02P,$%     @ 6SJ;5DP8M <+%P  "ZL
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M-2"T7(75?FBO[(XPK-<8UGG"0-HK>TMH=6Q','T!7+>*D6_'I_F+.%U96$G
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M\,]:Y$_F_[[@3Y!_D;*!_9H.D,Y UNJK#]MGC\/C$[5%^4\EN0;8CHCCBW\
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MI'!53ME?SF-S>>@AR!2QN%X[FP/+B)+4,8>B,Y#N>>B<A3P/.:*9Q"1ZPND
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M ^X3J//LYJ:\ZBB37^!I&)IYV;_Y[$ZO$M=$:YH(FI9'SQ@@7!&0:($ *3<
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MF-<:U<[#3WF>B]FM4#6T]KOZL;IONWPQ-N^=JQ92*$)5,@1BA1@@C"K L$R
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M_!]02P$"% ,4    " !;.IM6Y4#:Z;-9  !Y>P4 %@              @ $
M    8F%X+3(P,C,P,S,Q>&5X.3DQ+FAT;5!+ 0(4 Q0    ( %LZFU9,&+0'
M"Q<   NK   0              "  >=9  !B87@M,C R,S T,C<N:'1M4$L!
M A0#%     @ 6SJ;5KV5EE67 P  G0\  !               ( !('$  &)A
M>"TR,#(S,#0R-RYX<V102P$"% ,4    " !;.IM6VEV-@1D*  "M3   %
M            @ 'E=   8F%X+3(P,C,P-#(W7V1E9BYX;6Q02P$"% ,4
M" !;.IM6H&,K9D<0  #>F@  %               @ $P?P  8F%X+3(P,C,P
M-#(W7VQA8BYX;6Q02P$"% ,4    " !;.IM69%@0V9P)  #V3@  %
M        @ &ICP  8F%X+3(P,C,P-#(W7W!R92YX;6Q02P4&      8 !@"&
) 0  =YD

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
